U-Ploid Biotechnologies to Present Five Scientific Abstracts at Fertility 2026

Edinburgh, UK - 8 January 2026 U-Ploid Biotechnologies, a biotechnology company developing next-generation reproductive therapeutics to address age-related fertility decline, today announced that five scientific abstracts have been accepted for presentation at Fertility 2026 in Edinburgh. The presentations take place today, 8 January 2026.

The accepted work spans preclinical development, translational biology, and patient-centred clinical research, reflecting U-Ploid’s integrated approach to addressing age-related oocyte aneuploidy and the biological limits of current IVF practice. The abstracts were developed in collaboration with Care Fertility and The Fertility Alliance, combining clinical, patient, and research expertise.

One abstract relates to preclinical evaluation of Lyvanta™, U-Ploid’s lead intra-oocyte therapeutic programme, examining mechanisms of chromosomal error in ageing oocytes and the potential for targeted intervention to address meiotic mis-segregation. The presentation forms part of the company’s broader programme to translate fundamental oocyte biology into therapeutic strategies for improving egg quality.

A second abstract draws on a large, multi-centre dataset of ICSI cycles to characterise the prevalence and distribution of immature oocytes across maternal age groups, exploring their relevance for research applications and future therapeutic development in age-related infertility.

Three additional abstracts focus on the clinical and patient context for introducing next-generation IVF therapeutics. These include studies examining perceived treatment burden and openness to innovation, intended persistence with further IVF cycles as a proxy for unmet need, and patient preferences around clinical-trial design for novel reproductive interventions. Together, this work is intended to inform ethically robust, patient-centred approaches to first-in-human and early-phase fertility studies.

“These presentations reflect the breadth of our programme, from preclinical biology through to patient-centred clinical strategy,” said Jordan Abdi, MD MSc, Co-Founder and CEO of U-Ploid. “Fertility 2026 provides an important forum to engage with the scientific and clinical community as we continue to advance a new biological approach to addressing age-related infertility.”

U-Ploid is represented at the conference by Dr Alexandre Webster, Co-Founder and Chief Scientific Officer, and Eirini Bellou, PhD, Senior Applications Scientist, who are presenting the work and engaging with clinicians, embryologists, and research collaborators throughout the meeting.

About U-Ploid Biotechnologies

U-Ploid Biotechnologies is a venture-backed biotechnology company developing next-generation reproductive therapeutics to address the global challenge of age-related infertility. Co-founded by Jordan Abdi, Chloe Charalambous, and Alexandre Webster, U-Ploid is pioneering innovative solutions to improve IVF outcomes and expand the window of reproductive opportunity. The company’s technology is designed to increase the quality of older eggs and support healthy pregnancies. U-Ploid is committed to improving access to fertility care and envisions a future where anyone who wants to start a family can.

Media Contact

press@u-ploid.com

www.u-ploid.com

‍